EUVIMEDEUVIMED entdecken
Crossref

Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma

Jan-Michel Heger iD, Laman Mammadova, Julia Mattlener iD, Sophia Sobesky, Melita Cirillo iD, Janine Altmüller, Elisabeth Kirst, Sarah Reinke, Wolfram Klapper, Paul J Bröckelmann iD, Justin Ferdinandus iD, Helen Kaul und 17 weitere

Journal of Clinical Oncology · 10.12.2024 · 42 (35) · 4218-4230

DOI: 10.1200/jco.23.01867 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.12.2024. Verfasst von Jan-Michel Heger und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University of Cologne, Medical Faculty and Universi…. Hauptthemen laut MEDLINE: Hodgkin Disease, Circulating Tumor DNA. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 53 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Current clinical challenges in Hodgkin lymphoma (HL) include difficult-to-treat relapsed/refractory disease and considerable long-term toxicities of treatment. Since clinical risk factors lack discriminatory power, intensity of therapy is mainly based on tumor burden. Exploring HL genetics and tumor microenvironment (TME) might provide valuable insights for improved risk stratification. MATERIALS AND METHODS In this study, we applied circulating tumor DNA sequencing to 243 patients obtained from pivotal German Hodgkin Study Group trials to identify subtypes of HL. Independent validation of the subtypes was performed in 96 patients treated in the EuroNet-PHL-C2 study. Outcome differences of subtypes were assessed in an event-enriched clinical validation cohort comprising 72 patients from the HD21 trial, using a refined, validated, and clinically feasible assay. RESULTS We propose a biologic classification of HL consisting of three distinct subtypes: inflammatory immune escape HL is characterized by frequent copy-number variations including immune escape variants such as high-level amplifications of the PD-L1 locus and an inflammatory TME. Virally-driven HL is associated with Epstein-Barr virus and/or human herpesvirus 6 and an inflammatory TME with neutrophils and macrophages, while the tumor mutational burden (TMB) is low. Oncogene-driven HL is defined by a high TMB, recurrent mutations in oncogenic drivers such as TNFAIP3 , ITPKB , and SOCS1 , and a cold TME. A refined and validated assay version aiming at clinically feasible risk stratification showed significant progression-free survival differences between subtypes. In addition, assessment of minimal residual disease (MRD) allowed for the detection of patients at very high risk of relapse within the subtypes. CONCLUSION We propose a clinically feasible, noninvasive method for individualized risk stratification and MRD monitoring in patients with HL on the basis of circulating tumor DNA sequencing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hodgkin DiseaseCirculating Tumor DNAHumansFemaleMaleRisk AssessmentAdultMiddle AgedTumor MicroenvironmentYoung AdultAgedAdolescentBiomarkers, TumorMutation

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany.
  • Cancer Center Cologne Essen-Partner Site Cologne, CIO Cologne, University of Cologne, Cologne, Germany.
  • Cologne Lymphoma Working Group (CLWG), Cologne, Germany.
  • Mildred Scheel School of Oncology Aachen Bonn Cologne Düsseldorf (MSSO ABCD), Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.
  • German Hodgkin Study Group (GHSG), Cologne, Germany.
  • University of Western Australia and Royal Perth Hospital, Perth, Australia.

ORCID-Profile: Jan-Michel Heger, Julia Mattlener, Melita Cirillo, Paul J Bröckelmann, Justin Ferdinandus, Gundolf Schneider, Jessica Schneider, Julia Katharina Schleifenbaum, Sabine Awerkiew, Florian Klein, Peter Nürnberg, Michael Hallek, Davide Rossi, Christine Mauz-Körholz, Peter Borchmann, Bastian von Tresckow

Zitieren

APA

Heger, J. M., Mammadova, L., Mattlener, J., Sobesky, S., Cirillo, M., Altmüller, J., Kirst, E., Reinke, S., Klapper, W., Bröckelmann, P. J., Ferdinandus, J., Kaul, H., Schneider, G., Schneider, J., Schleifenbaum, J. K., Ullrich, R. T., Freihammer, M., Awerkiew, S., Lohmann, M., …, & Borchmann, S. (2024). Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma. Journal of Clinical Oncology, 42(35), 4218-4230. https://doi.org/10.1200/jco.23.01867

Vancouver

Heger JM, Mammadova L, Mattlener J, Sobesky S, Cirillo M, Altmüller J, et al. Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma. Journal of Clinical Oncology. 2024;42(35):4218-4230. doi:10.1200/jco.23.01867

BibTeX
@article{Heger2024,
  author = {Heger, Jan-Michel and Mammadova, Laman and Mattlener, Julia and Sobesky, Sophia and Cirillo, Melita and Altmüller, Janine and Kirst, Elisabeth and Reinke, Sarah and Klapper, Wolfram and Bröckelmann, Paul J and Ferdinandus, Justin and Kaul, Helen and Schneider, Gundolf and Schneider, Jessica and Schleifenbaum, Julia Katharina and Ullrich, Roland T and Freihammer, Max and Awerkiew, Sabine and Lohmann, Mia and Klein, Florian and Nürnberg, Peter and Hallek, Michael and Rossi, Davide and Mauz-Körholz, Christine and Gattenlöhner, Stefan and Bräuninger, Andreas and Borchmann, Peter and von Tresckow, Bastian and Borchmann, Sven},
  title = {Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {35},
  pages = {4218--4230},
  doi = {10.1200/jco.23.01867}
}
Kostenlos starten →